Abstract
Heart failure (HF) is a major public health problem. Early identification of at-risk individuals could allow for interventions that reduce morbidity or mortality. The community-based FINRISK Microbiome DREAM challenge (synapse.org/finrisk) evaluated the use of machine learning approaches on shotgun metagenomics data obtained from fecal samples to predict incident HF risk over 15 years in a population cohort of 7231 Finnish adults (FINRISK 2002, n=559 incident HF cases). Challenge participants used synthetic data for model training and testing. Final models submitted by seven teams were evaluated in the real data. The two highest-scoring models were both based on Cox regression but used different feature selection approaches. We aggregated their predictions to create an ensemble model. Additionally, we refined the models after the DREAM challenge by eliminating phylum information. Models were also evaluated at intermediate timepoints and they predicted 10-year incident HF more accurately than models for 5- or 15-year incidence. We found that bacterial species, especially those linked to inflammation, are predictive of incident HF. This highlights the role of the gut microbiome as a potential driver of inflammation in HF pathophysiology. Our results provide insights into potential modeling strategies of microbiome data in prospective cohort studies. Overall, this study provides evidence that incorporating microbiome information into incident risk models can provide important biological insights into the pathogenesis of HF.
Competing Interest Statement
Illumina, Inc., and Janssen Pharmaceutica provided additional support by sponsoring the Center for Microbiome Innovation at the University of California San Diego. T.N. has received honoraria for speaking engagements from Servier and AstraZeneca. V.S. has had research collaboration with Bayer AG, unrelated to this study. J.S.-R. has received funding from GSK, Pfizer and Sanofi, and fees/honoraria from Travere Therapeutics, Stadapharm, Astex, Pfizer and Grunenthal. M.I. is a trustee of the Public Health Genomics (PHG) Foundation, a member of the Scientific Advisory Board of Open Targets, and has a research collaboration with AstraZeneca unrelated to this study. R.K. is a cofounder of Micronoma and Biota, holding stock for Gencirq, Cybele, Biomesense, Micronoma, and Biota, serve as Scientific Advisory Board in Gencirq, DayTwo, Biomesense, and Micronoma and serve as consultant for DayTwo, Cybele, and Biomesense.
Funding Statement
This work was supported by COST (European Cooperation in Science and Technology) and Informatics4Life, a joint initiative founded by the Klaus-Tschira Foundation. P.P.E. is funded by Turku Collegium for Science, Medicine, and Technology (TCSMT). R.T.L. & E.K. are funded by Informatics4life. T.D.L. was supported by the Finnish Cultural Foundation. L.E.F was supported by the Pharmacology Training Grant (T32 GM007635) through the University of Colorado Anschutz Medical Campus. T.N. is funded by the Sigrid Jusélius Foundation, the Finnish Foundation for Cardiovascular Research, and the Research Council of Finland (grants 321531 and 354447). A.S.H. was supported by the Research Council of Finland (grant 321356). J.S.-R. has received funding from GSK, Pfizer and Sanofi, and fees/honoraria from Travere Therapeutics, Stadapharm, Astex, Pfizer and Grunenthal. L.L. was supported by Research Council of Finland (grant 330887).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Coordinating Ethics Committee of the Helsinki University Hospital District approved the study protocol for FINRISK 2002 (Ref. 558/E3/2001)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Code and model descriptions during the final phase of the challenge is available online, which may be accessed by the hyperlinks listed in Supp. Table 3. The synthetic and real data used in the challenge can be obtained upon a reasonable request from THL Biobank, https://thl.fi/en/web/thl-biobank/for-researchers/ due to sensitive health information of individuals.
